<DOC>
	<DOCNO>NCT00788515</DOCNO>
	<brief_summary>The primary objective compare potential next-day residual effect volinanserin 2 mg/day lormetazepam 1 mg/day measure sleepiness morning use patient 's sleep questionnaire 4 week treatment patient chronic primary insomnia sleep maintenance difficulty . Secondary objective compare clinical safety product , include potential rebound insomnia withdrawal symptom treatment discontinuation , compare efficacy product subjective sleep parameter compare effect product patient 's daytime functioning .</brief_summary>
	<brief_title>Comparison Volinanserin Lormetazepam Treatment Insomnia Characterized Sleep Maintenance Difficulties</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Lormetazepam</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Outpatients Primary Insomnia accord Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) criterion Based patient 's information , patient spent le 6.5 hour 9.0 hour , bed , night , precede two week Based patient 's information , patient complains less one hour wakefulness sleep onset least 3 night per week precede month Disturbances sleep maintenance parameter base patient 's sleep questionnaire runin period differ predefined criterion . Pregnant breastfeed woman woman childbearing potential without effective contraceptive method birth control Night shift worker individual nap 3 time per week Consumption xanthinecontaining beverage ( i.e. , tea , coffee cola ) comprise 5 cup glass per day The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>insomnia</keyword>
	<keyword>sleep maintenance</keyword>
</DOC>